Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The main points are briefly summarised in these bullet points below, provided by Viking Therapeutics earnings press release: Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26 Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing
It maintains the integrity of red blood cells and prevents damage to them
Ozempic (semaglutide) Disease area(s): Metabolic diseases Manufacturer(s): Novo Nordisk 2024 Sales (USD): $17.45 billion Why it sold so well: Novo Nordisks GLP-1 blockbuster for type 2 diabetes continued its impressive growth in 2024, with sales increasing by 26% year-over-year to DKK 120.3 billion ($17.45 billion)
Storage: Store at 28C
US$ 29.49
US$ 20.58
US$ 29.92
